Keros Therapeutics to Present at Key Healthcare Conferences
![Keros Therapeutics to Present at Key Healthcare Conferences](https://investorshangout.com/images/blog/ihnews-Keros%20Therapeutics%20to%20Present%20at%20Key%20Healthcare%20Conferences.jpg)
Keros Therapeutics to Present at Key Healthcare Conferences
Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, has announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at several upcoming healthcare conferences.
Participation in Significant Conferences
Keros will be engaging in discussions and presentations at noteworthy healthcare events showcasing their advancements and insights in biopharmaceutical development. Understanding that these conferences provide a critical platform for networking and promoting innovative treatments, the following are details regarding their presentations:
Morgan Stanley 22nd Annual Global Healthcare Conference
Date and Time: Wednesday, September 4, 2024, at 4:05 p.m. Eastern time
Format: Fireside Chat Presentation
2024 Wells Fargo Healthcare Conference
Date and Time: Thursday, September 5, 2024, at 10:15 a.m. Eastern time
Format: Fireside Chat Presentation
2024 Cantor Global Healthcare Conference
Date and Time: Thursday, September 19, 2024, at 8:35 a.m. Eastern Time
Format: Fireside Chat Presentation
Access to Archived Presentations
For investors and those interested in Keros Therapeutics' developments, an archived replay of each presentation will be available in the Investors section of the Keros website following the conclusion of each event. It is anticipated that this resource will be accessible for up to 90 days post-event, ensuring that attendees and stakeholders can review the information shared during the presentations.
About Keros Therapeutics, Inc.
Keros Therapeutics is dedicated to addressing various medical conditions through innovative treatments. They focus on the intricacies of TGF-ß proteins, which play a crucial role in numerous bodily functions including the growth, repair, and maintenance of diverse tissues like blood, bone, and muscle. Through their research, Keros has demonstrated a commitment to developing therapies that offer meaningful benefits to patients. Their leading product candidate, elritercept (KER-050), aims to address low blood cell counts, including anemia and thrombocytopenia, especially in patients facing myelodysplastic syndromes and myelofibrosis. Additionally, cibotercept (KER-012) is under development for pulmonary arterial hypertension, while KER-065 targets conditions related to obesity and neuromuscular diseases.
Contacting Keros Therapeutics
For investor inquiries, Justin Frantz can be contacted via email at jfrantz@kerostx.com or by phone at 617-221-6042.
Frequently Asked Questions
What is Keros Therapeutics known for?
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders related to TGF-ß signaling.
Which healthcare conferences will Keros participate in?
Keros will present at the Morgan Stanley 22nd Annual Global Healthcare Conference, the 2024 Wells Fargo Healthcare Conference, and the 2024 Cantor Global Healthcare Conference.
What is the significance of the TGF-ß protein family?
The TGF-ß protein family is crucial for regulating growth, repair, and maintenance of various tissues in the body, making it a key target for therapeutic development.
What are Keros' leading product candidates?
Keros' leading product candidates include elritercept (KER-050) for low blood cell counts, cibotercept (KER-012) for pulmonary arterial hypertension, and KER-065 for obesity and neuromuscular diseases.
How can investors access Keros' presentations?
Archived replays of Keros' presentations will be available in the Investors section of their website for up to 90 days following each event.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Coiled Tubing Market to Reach $6.5 Billion Driven by Innovation
- Challenges and Advances in Sickle Cell Disease Treatments
- FFW Corporation Declares $0.30 Quarterly Dividend
- NewtekOne, Inc. CEO Barry Sloane to Attend Key Conference
- AUGA group, AB Investor Conference Webinar Details
- Public Opening Position Disclosure by Rathbones Group Plc
- Loupe Offers Exciting Rewards for Topps Chrome Basketball
- DCHFA Relaunches ReMIT Program to Assist Seniors
- RealManage Achieves 2024 Great Place to Work Certification
- Maternal Nutrition Products Market Set to Reach $38.66 Billion